An interventional study of Low-dose computed tomography (LDCT) in Testicular Cancer, sponsored by University Health Network, Toronto. Active, not recruiting at 1 site in Canada. Open to male participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-06-23.
Sponsored by University Health Network, Toronto · Not applicable, Interventional, and Diagnostic
Patients with primary germ cell cancer of the testicles confined to the testis can avoid adjuvant treatment by entering a surveillance protocol. In the surveillance protocol, patients are followed for up to ten years with serial computed tomography scans to detect recurrence. Multiple CT scans expose patients to a significant amount of radiation, which may be associated with an increased risk of secondary malignancies. This study hypothesizes that low dose CT scans are as effective as standard dose CT scans in detecting disease recurrence in this setting and will significantly reduce radiation exposure in this group of patients.
189 studies on the registry are indexed under Testicular Neoplasms; 53 are open to participants now.
This study's enrollment of 251 is above the median of 59 across 122 interventional studies indexed under Testicular Neoplasms.
Browse Testicular Neoplasms studies →University Health Network, Toronto is the lead sponsor of 1,411 studies on the registry; 292 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 3 (18%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patients with testicular germ cell cancer who have either been newly diagnosed, or have stage I cancer already on surveillance program will undergo conventional and low dose CT. Based on the imaging, they may undergo a surveillance program using low-dose CT.
Diagnostic Test: Low-dose computed tomography (LDCT)
In phase A of the study, patients will undergo conventional CT along with low dose CT. If patients have a normal conventional CT and a satisfactory low dose CT, they will move onto Phase B of the study in which they will undergo surveillance using low-dose CT. Three outcomes are possible with low-dose CT surveillance: 1. Normal LDCT: \- Patient continues on the study (i.e. continued surveillance) 2. Suspicious LDCT: \- Will undergo conventional CT and if results are normal, patient will continue on study. If conventional CT is abnormal, they will be taken off study 3. Elevated serum tumour markers or other evidence of metastatic disease: * Patient goes off study
Difference in size of the retroperitoneal lymph node mass
The difference in size of lymph node mass at the time of relapse between low dose CT and conventional CT. This is to evaluate the effectiveness of using low-dose CT in patients undergoing surveillance.
Time frame: 9 years
Time on surveillance
Amount of time patient is on surveillance before detection of relapse.
Time frame: 6 years
Amount of false positive rate of LDCTs
Time frame: 6 years
Proportion of patients unsuitable for LDCT surveillance
Gather information on proportion of patients who were unsuitable for LDCT surveillance due to poor image quality
Time frame: 6 years
Proportion of patients who have to discontinue LDCT surveillance
Gather information on proportion of patients who had to discontinue LDCT surveillance due to poor image quality.
Time frame: 6 years
Amount of prospective identification of first modality to detect relapse
To prospectively identify the first modality to detect relapse (patient symptoms, clinical examination, tumour marker, imaging)
Time frame: 6 years
Proportion of disease-free survival
To document proportion of disease-free survival
Time frame: 6 years
Proportion of overall survival
To document proportion of overall survival
Time frame: 6 years
Amount of prospective documentation of treatment for testicular germ cell cancer relapse
To prospectively document the treatment types for patients who have relapsed.
Time frame: 6 Years
Plan to share: Undecided
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Health Network, Toronto